復星醫藥(02196.HK)參與設立私募股權投資基金 發掘中早期生物醫藥成長性企業
格隆匯7月28日丨復星醫藥(02196.HK)公吿,公司與控股子公司/企業南京復宜在內的其他5方投資人擬共同出資設立目標基金(以下簡稱“本次投資”)。
目標基金計劃募集資金人民幣5億元,最高不超過5.5億元;其中,首期擬募集資金總額為人民幣4.05億元,於首期擬募集中,復星醫藥(作為LP)、南京復宜(作為GP)擬分別以現金出資人民幣2.3億元、人民幣500萬元認繳目標基金中的等值財產份額。
本次通過對目標基金的投資,旨在重點發掘中早期生物醫藥領域的成長性企業,並通過獲得、持有及處置投資項目,為合夥人獲取長期投資回報,加強本集團大健康產業佈局。本次投資完成後,目標基金將納入集團合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.